Log in

CNSX:CURE - Biocure Technology Stock Price, Forecast & News

Today's Range N/A
50-Day Range
MA: $0.29
52-Week Range N/A
Volume44,500 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Biocure Technology Inc. develops and commercializes biosimilar pharmaceutical products in South Korea. The company is developing Interferon Beta 1b for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing a foot and mouth disease vaccine, a hair growth production product, and a breast cancer detection kit. Biocure Technology Inc. is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A

Receive CURE News and Ratings via Email

Sign-up to receive the latest news and ratings for CURE and its competitors with MarketBeat's FREE daily newsletter.

Biocure Technology (CNSX:CURE) Frequently Asked Questions

What is Biocure Technology's stock symbol?

Biocure Technology trades on the CNSX under the ticker symbol "CURE."

Has Biocure Technology been receiving favorable news coverage?

Headlines about CURE stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biocure Technology earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Biocure Technology.

Who are some of Biocure Technology's key competitors?

What other stocks do shareholders of Biocure Technology own?

Who are Biocure Technology's key executives?

Biocure Technology's management team includes the folowing people:
  • Dr. Sang Mok Lee Ph.D., Pres, CEO & Director (Age 53)
  • Mr. Konstatin Lichtenwald, CFO & Director
  • Mr. Marco Nonni, Consultant

How do I buy shares of Biocure Technology?

Shares of CURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biocure Technology's official website?

The official website for Biocure Technology is http://www.biocuretech.com/.

How can I contact Biocure Technology?

The company can be reached via phone at 604-609-7149.

MarketBeat Community Rating for Biocure Technology (CNSX CURE)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  58
MarketBeat's community ratings are surveys of what our community members think about Biocure Technology and other stocks. Vote "Outperform" if you believe CURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel